Evidence map›Paper›PMID 37168350›Full record

ArticleAmerican journal of cancer research2023

Repurposing NFκB and HDAC inhibitors to individually target cancer stem cells and non-cancer stem cells from mucoepidermoid carcinomas.

Luan César Silva, Gabriell Bonifácio Borgato, Vivian Petersen Wagner, Manoela Domingues Martins, Márcio Ajudarte Lopes, Alan Roger Santos-Silva, Gilberto De Castro, Luiz Paulo Kowalski, Cristiane Helena Squarize, Pablo Agustin Vargas and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Luan César SilvaDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Gabriell Bonifácio BorgatoDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Vivian Petersen WagnerAcademic Unit of Oral and Maxillofacial Medicine and Pathology, Department of Clinical Dentistry, University of Sheffield Sheffield, UK.
Manoela Domingues MartinsDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Márcio Ajudarte LopesDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Alan Roger Santos-SilvaDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Gilberto De CastroServiço de Oncologia Clínica, Instituto do Câncer do Estado de São Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo São Paulo, SP, Brazil.
Luiz Paulo KowalskiDepartment of Head and Neck Surgery, University of Sao Paulo Medical School and Head and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center São Paulo, Brazil.
Cristiane Helena SquarizeLaboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry Ann Arbor, Michigan, USA.
Pablo Agustin VargasDepartment of Oral Diagnosis, Piracicaba Dental School, University of Campinas Piracicaba, São Paulo, Brazil.
Rogerio Moraes CastilhoLaboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry Ann Arbor, Michigan, USA.
Methodist University of Piracicaba · BRUniversity of Michigan · USAC Camargo Hospital · BRInstituto do Câncer do Estado de São Paulo · BRUniversidade Federal do Rio Grande do Sul · BRUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance remains a major obstacle in the treatment of mucoepidermoid carcinomas (MEC) leading to tumor recurrence, disease progression, and metastasis. Emerging evidence suggests that drug resistance is mediated by the presence of a highly adaptative subpopulation of cancer cells known as cancer stem cells (CSC). We have previously reported that solid tumors use NFkB signaling as a chemotherapy-resistant mechanism. We have also shown that interfering with the epigenome of solid tumors is an effective strategy to control the population of CSC. Here, we sought to investigate the effects of the NFkB inhibitor emetine and the HDAC inhibitor SAHA on the biology of MEC CSC and assessed whether this combination therapy would favor the standard of care therapy comprised of the administration of Cisplatin (CDDP). Our findings suggested that the administration of low concentrations of emetine and SAHA is more effective in disrupting CSC in MEC, while the administration of emetine in combination with CDDP constitutes an effective therapy to target non-CSC MEC tumor cells.

Indexed as

cancer stem cellschemotherapyepigeneticHead and neck tumorsNFκBsalivary gland cancertarget therapy

Identifiers

PMID37168350
PMCPMC10164805
OpenAlexW4376226093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.